The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop

Comparative effectiveness research (CER) is the study of existing treatments or ways to deliver health care to determine what intervention works best under specific circumstances. CER evaluates evidence from existing studies or generates new evidence, in different populations and under specific conditions in which the treatments are actually used. CER does not embrace one research design over another but compares treatments and variations in practice using methods that are most likely to yield widely generalizable results that are directly relevant to clinical practice. Treatments used in transfusion medicine (TM) are among the most widely used in clinical practice, but are among the least well studied. High‐quality evidence is lacking for most transfusion practices, with research efforts hampered by regulatory restrictions and ethical barriers. To begin addressing these issues, the National Heart, Lung, and Blood Institute convened a workshop in June 2011 to address the potential role of CER in the generation of high‐quality evidence for TM decision making. Workshop goals were to: 1) evaluate the current landscape of clinical research, 2) review the potential application of CER methods to clinical research, 3) assess potential barriers to the use of CER methodology, 4) determine whether pilot or vanguard studies can be used to facilitate planning of future CER research, and 5) consider the need for and delivery of training in CER methods for researchers.

[1]  Y. Khaliq,et al.  Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans , 2012 .

[2]  J. Hirsh,et al.  The effect of blood storage duration on in‐hospital mortality: a randomized controlled pilot feasibility trial , 2012, Transfusion.

[3]  Jiajie Zhang,et al.  Coordination and management of multicenter clinical studies in trauma: Experience from the PRospective Observational Multicenter Major Trauma Transfusion (PROMMTT) Study. , 2012, Resuscitation.

[4]  L. Critchley,et al.  Prevalence of Survivor Bias in Observational Studies on Fresh Frozen Plasma: Erythrocyte Ratios in Trauma Requiring Massive Transfusion , 2012, Anesthesiology.

[5]  B. Chaitman,et al.  Liberal or restrictive transfusion in high-risk patients after hip surgery. , 2011, The New England journal of medicine.

[6]  C. Ko,et al.  Evidence-based medicine in surgery: the importance of both experimental and observational study designs. , 2011, JAMA.

[7]  D. Cook,et al.  The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. , 2011, Transfusion medicine reviews.

[8]  J. Ware,et al.  Pragmatic trials--guides to better patient care? , 2011, The New England journal of medicine.

[9]  J. Lacroix,et al.  Impact clinique de la durée de conservation des globules rouges avant transfusion , 2011 .

[10]  S. Glynn,et al.  A multidisciplinary “think tank”: the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute–sponsored 2009 state‐of‐the‐science symposium , 2011, Transfusion.

[11]  Mehrdad Alemozaffar,et al.  Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy: description of technique and outcomes. , 2011, European urology.

[12]  D. Dilts,et al.  A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies , 2010, Clinical Cancer Research.

[13]  S. Glynn,et al.  Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium. , 2010, Transfusion medicine reviews.

[14]  S. Hopewell,et al.  Where are the systematic reviews in transfusion medicine? A study of the transfusion evidence base. , 2010, Transfusion medicine reviews.

[15]  Mark McClellan,et al.  Comparative effectiveness research: Policy context, methods development and research infrastructure , 2010, Statistics in medicine.

[16]  P. Scardino,et al.  Validation study of a web-based assessment of functional recovery after radical prostatectomy , 2010, Health and quality of life outcomes.

[17]  Francis S Collins,et al.  Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. , 2010, JAMA.

[18]  Richard Platt,et al.  Cluster Randomized Trials in Comparative Effectiveness Research: Randomizing Hospitals to Test Methods for Prevention of Healthcare-Associated Infections , 2010, Medical care.

[19]  J. Vincent,et al.  Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? , 2009, Transfusion.

[20]  S. Yusuf,et al.  Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs , 2009, Clinical trials.

[21]  M. Maclure Explaining pragmatic trials to pragmatic policy-makers , 2009, Canadian Medical Association Journal.

[22]  Ian Harvey,et al.  A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers , 2009, Canadian Medical Association Journal.

[23]  Paige E. Waterman,et al.  An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. , 2009, The Journal of trauma.

[24]  P. Scardino,et al.  The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost , 2009, Trials.

[25]  Richard L. George,et al.  The relationship of blood product ratio to mortality: survival benefit or survival bias? , 2009, The Journal of trauma.

[26]  A. Peitzman,et al.  An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. , 2008, The Journal of trauma.

[27]  J. Michalek,et al.  Increased Plasma and Platelet to Red Blood Cell Ratios Improves Outcome in 466 Massively Transfused Civilian Trauma Patients , 2008, Annals of surgery.

[28]  J. Duchesne,et al.  Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? , 2008, The Journal of trauma.

[29]  A. Sauaia,et al.  Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? , 2008, The Journal of trauma.

[30]  Andrew J Vickers,et al.  Do we want more cancer patients on clinical trials If so, what are the barriers to greater accrual , 2008, Trials.

[31]  B. Cotton,et al.  Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. , 2008, The Journal of trauma.

[32]  T. Mihaljevic,et al.  Duration of red-cell storage and complications after cardiac surgery. , 2008, The New England journal of medicine.

[33]  J. Cutler,et al.  Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[34]  N. Mann,et al.  State trauma registries: survey and update-2004. , 2007, The Journal of trauma.

[35]  D. Fergusson,et al.  Clinical consequences of red cell storage in the critically ill , 2006, Transfusion.

[36]  Richard L Schilsky,et al.  Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Martineau,et al.  A Pilot Trial Evaluating the Clinical Effects of Prolonged Storage of Red Cells , 2005, Anesthesia and analgesia.

[38]  G. Rosner,et al.  Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Stryer,et al.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.

[40]  I. Chalmers,et al.  A controlled clinical trial in 1809? , 2002, Journal of epidemiology and community health.

[41]  B. Davis,et al.  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. , 2001, Controlled clinical trials.

[42]  E. Keeler,et al.  The Cost Effectiveness of Preoperative Autologous Blood Donations , 1995 .

[43]  R. Bast,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[45]  T. Francis Evaluation of the 1954 poliomyelitis vaccine field trial; further studies of results determining the effectiveness of poliomyelitis vaccine (Salk) in preventing paralytic poliomyelitis. , 1955, Journal of the American Medical Association.

[46]  L. Kovacs,et al.  The age of red blood cells in premature infants (ARIPI) randomized controlled trial: study design. , 2009, Transfusion medicine reviews.

[47]  B. Custer,et al.  Cost-effectiveness analysis: what it really means for transfusion medicine decision making. , 2009, Transfusion medicine reviews.